A Study of SGB-7342 in Subjects With Obesity or Overweight
ConditionObesity & Overweight
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorSuzhou Sanegene Bio Inc.
About this trial
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
Eligibility criteria
Qualifiers
Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
Have a stable body weight within 3 months
Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.
Disqualifiers
A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)> 1.5 × ULN, and deemed clinically significant by the Investigators
Trial design
Treatments tested in this trial
- SGB-7342
- SGB-7342-Matching placebo
Treatment groups
45 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov